Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | SERPINE1 | P05121 | 4/20 | 0.67 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.67 |
| ▸ | HTR6 | P50406 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481061 | 0.83 | MAPT (0.86) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1847175 | 0.80 | SIRT6 (1.00) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20640023 | 0.79 | MAPT (0.79) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2762465 | 0.79 | MAPT (0.79) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2462482 | 0.79 | MAPT (0.79) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2389106 | 0.79 | MAPT (0.71) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27943723 | 0.79 | MAPT (0.77) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1844704 | 0.78 | HTR6 (1.00) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2389029 | 0.78 | MAPT (0.80) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13528776 | 0.78 | MAPT (0.65) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | MAPT 2258/4885NPSR1 257/4885CYP1A2 4717/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | MAPT 3379/4885NPSR1 188/4885CYP1A2 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.